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2ABSTRACT
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and hepatocellular 
carcinoma, yet fully efficacious treatments are missing. In the present work, we investigated 
RNA interference, a specific gene silencing process mediated by small interfering RNA 
(siRNA) duplexes, as an antiviral strategy for HCV. Synthetic siRNAs were designed to 
target conserved sequences of the HCV 5' nontranslated region located in a functional, stem-
loop structured domain of the HCV internal ribosome entry site (IRES), which is crucial for 
polyprotein translation initiation. Several siRNAs dramatically reduced or even abrogated the 
replication of selectable subgenomic HCV replicons upon cotransfection of human hepatoma 
cells with viral target and siRNAs, or transfection of cells supporting autonomous replication 
of HCV replicon with siRNAs. Importantly, three siRNAs also proved capable of strongly 
inhibiting virus production in cell culture. One siRNA, targeting a sequence highly conserved 
across all genotypes that forms a critical pseudoknot structure involved in translation, was 
identified as the most promising therapeutic candidate. These results indicate that HCV life 
cycle can be efficiently blocked using properly-designed siRNAs that target functionnally-
important, highly conserved sequences of the HCV IRES, offering a novel approach to 
develop IRES-based antiviral treatment of chronic HCV infections.
3INTRODUCTION
Persistent hepatitis C virus (HCV) infection is established in the liver with high frequency, 
leading to the development of chronic hepatitis, and possibly liver cirrhosis and 
hepatocellular carcinoma at later stages. Chronic HCV infection concerns 2.2% of the 
World’s population and is known to be the leading cause of liver transplantation in 
developped countries. No vaccine is available for HCV and the current treatment, consisting 
in the administration of pegylated interferon  and ribavirine proved to have limited efficacy 
on certain HCV genotypes, as well as general adverse effects [reviewed in Ref. 1]. The 
development of alternative, specific therapies for chronic HCV infection is thus a major 
public health objective. 
HCV, as a member of the Flaviviridae family, contains a single-stranded positive RNA 
genome that encodes a unique precursor polyprotein which is further processed into structural 
proteins and nonstructural proteins ensuring genome replication. The long open reading frame 
is flanked by 5’ and 3’ nontranslated regions (NTR) that are highly conserved among the 
majority of HCV genotypes and contain elements that are essential for genome replication 
[reviewed in Ref. 1]. In addition, HCV 5'NTR contains a highly structured element, an 
internal ribosomal entry site (IRES), that is essential for the initiation of HCV polyprotein 
translation [2]. Anti-HCV drug development has been hampered by the lack of both efficient 
cell culture systems that support virus replication and accessible animal models. Until 
recently, HCV subgenomic RNA replicon systems [3] only allowed to assay the inhibitory 
effect of antiviral candidates on HCV genome replication in vitro, in human hepatoma cells. 
The recent development of stable cell culture systems permitting robust production of 
4infectious HCV particles in vitro, based on the JFH-1 strain of HCV genotype 2a [4], will 
facilitate the investigation and testing of new antiviral strategies. In addition, alternative 
animal models which have been recently developed are promising for the evaluation of 
candidate antiviral therapeutics. These include transgenic mice engrafted with human 
hepatocytes [5], as well as nonendangered primate species (tamarins, marmosets) infected by 
GB virus B (GBV-B), a hepatotropic virus that is closely related to HCV [6, 7], or by GBV-B 
derivatives containing functional HCV sequences [8]. 
Among possible therapeutic strategies, RNA interference (RNAi) is an attractive path to 
explore. First described as a natural defense mechanism against plant viruses, RNAi was 
subsequently shown to be a universal phenomenon of post-transcriptional gene silencing that 
is initiated by double-stranded RNA and leads to specific degradation of homologous RNAs. 
This process involves the generation of 21-nucleotide short interfering RNAs (siRNAs) 
which, in association with a multiprotein complex named RNA induced silencing complex 
(RISC), are used as guides to target specific RNA substrates by Watson-Crick base pairing. 
Such siRNAs, when introduced directly into mammalian cells or expressed from viral 
vectors, can lead to the degradation of targeted sequences [reviewed in Ref. 9]. During the 
past few years, RNAi has been extensively investigated as an alternative specific therapy to 
treat cancers, genetic diseases, as well as infections by various human pathogens of medical 
importance, using both in vitro and in vivo model systems [reviewed in Refs. 10, 11]. RNA 
viruses, in particular viruses with liver tropism such as HCV, are ideal candidates for nucleic 
acid-based therapies which have been shown to predominantly target the liver [reviewed in 
Ref. 12]. Recently, various studies have reported on the variable inhibitory effect of HCV-
specific synthetic siRNAs or small hairpin RNAs (shRNAs) expressed from viral vectors that 
5target sequences encoding various HCV nonstructural proteins, as well as sequences within 
the 5’NTR [13-19]. These studies all relied on the use of HCV subgenomic or genomic 
replicon models in cell culture.
In the present work, we designed siRNAs targeting highly conserved sequences within the 
HCV 5'NTR. The efficiency of these HCV-specific siRNAs was first evaluated using 
previously described self-replicating HCV RNAs [20, 21]. This allowed us to select four 
siRNAs that abrogated or substantially reduced genome replication. Using these siRNAs in 
recently described cell culture systems supporting the production of genotype 2a JFH-1 [4] or 
chimeric 1a/2a (Delgrange et al., unpublished data) infectious particles, we demonstrated the 
successful silencing of HCV infection in cell culture.
RESULTS
Selection of siRNAs targeting HCV 5'NTR
To investigate the potency of virus-specific siRNAs to inhibit HCV infection, we selected 7 
siRNAs that target conserved sequences of the pivotal domain (domain III) of the HCV IRES 
within the 5'NTR [2] (Fig. 1a). This domain is particularly important for initiation of 
polyprotein translation, as it directly contacts 40S ribosomal subunits [22] and binds 
translation initiation factor 3, eIF3 [23]. Domain III has also been reported to be involved to 
some extent in genome replication [24]. siRNAs were designed essentially using previously 
described criteria, and in particular, whenever possible, asymetric thermostability of siRNA 
duplexes was respected [25, 26]. As a messenger, HCV positive strand RNA genome is an 
6ideal target for siRNAs, but it harbors strong secondary and tertiary structures, in particular 
within the IRES, which makes the design of optimal siRNAs difficult according to the criteria 
referenced above. In contrast, the high nucleotide conservation of this region permitted to 
identify siRNAs that were homologous to several HCV genotypes (Table 1). Selected siRNAs 
were named according to the nucleotide position within the genome of the H77 strain of HCV 
genotype 1a [27] that corresponds to the first 5' nucleotide targeted by the siRNA antisense 
strand : si205, si214, si240-1a, si240-1b, si244, si284, si313 (Table 1). siRNA si313 targets 
the 3' end of domain III and 5' end of domain IV involved in a pseudo-knot located upstream 
from the initiator codon (Fig. 1a). The sequence of all siRNAs, with the exception of si240, 
matched both HCV genotype 1a and 1b sequences present in the subgenomic replicons used 
in the first part of the study (Fig. 1b). Two siRNAs si240 (si240-1a and si240-1b) were thus 
synthesized with sequence homologous to either genotype 1a or 1b, respectively. When 
targeted to genotype 1b 5'NTR, si240-1a formed a G:U wobble base-pairing at position 18 of 
the siRNA antisense strand, whereas si240-1b formed an A:C mismatch with the genotype 1a 
replicon (Fig. 1c). The G:U non-canonical base-pairing is known to be non-disruptive in 
double-stranded RNA structures and both G:U wobble base-pairing and A:C mismatch, if 
present at certain positions of the siRNA, were recently reported to be well tolerated for 
siRNA-mediated gene silencing [28-31]. Therefore, we undertook to analyze the effect of 
si240-1a and si240-1b on both homologous and heterologous replicon targets. Finally, an 
irrelevant siRNA, referred to as siIRR (Table 1), previously used to target a sequence within 
the 5’NTR of a poliovirus strain [30], that did not share homology with HCV sequence, was 
used as a non-specific, negative control in these experiments. 
7Effect of siRNAs on the replication of reporter HCV subgenomic replicon
First, we evaluated whether selected siRNAs were able to inhibit the replication of an HCV 
subgenomic replicon (Ntat2ANeo) in cell culture, using a previously described system that 
allowed simple monitoring of RNA replication by measurement of an enzymatic activity, 
secreted alkaline phosphatase (SEAP) activity [21] (see Material and Methods and Fig. 1b). 
All HCV sequences of Ntat2ANeo replicon are derived from the N strain of genotype 1b, 
with the exception of the 5'NTR, which is derived from the H77 strain of genotype 1a. 
Following coelectroporation of En5-3 cells with 5 µg of in vitro-transcribed Ntat2ANeo RNA 
and 2 µg of each synthetic siRNA, culture supernatant was replaced daily with fresh medium 
during the first 4 days after transfection, then at 7 days post-transfection, and SEAP activity 
was measured in all culture supernatants collected. During the first 2 days, SEAP signals 
essentially reflected translation of the input RNAs, since SEAP levels were roughly similar in 
cells transfected with Ntat2ANeo replicon or with a replication-defective RNA encoding an 
inactive NS5B RNA polymerase deleted in its active site (∆GDD, see Material and Methods). 
RNA replication was then clearly detected between 3 and 7 days post-transfection (Fig. 2a, 
compare SEAP levels in cells transfected with Ntat2ANeo and ∆GDD). Co-transfection of the 
irrelevant siRNA, siIRR, did not significantly affect Ntat2ANeo replication (Fig. 2a). HCV-
specific siRNAs si214 and si284 showed only transient or no effect on HCV replication, 
respectively, and SEAP expression levels at 7 days post-transfection were similar to that 
induced by transfection of Ntat2ANeo alone (Fig. 2a). These two siRNAs were thus not 
further utilized in the course of our study. In sharp contrast, siRNAs si205, si240-1a, si240-
1b, si244 and si313 proved capable of abolishing HCV replication in this system, yielding 
SEAP levels as low as those obtained with replication-defective RNA ∆GDD. In the presence 
8of these siRNAs, SEAP levels were even slightly lower at days 1, 2 and 3 post-transfection 
than those obtained with ∆GDD, as a result of siRNA-mediated degradation of input RNAs, 
that were thus not available for translation (Fig. 2a). The inhibitory effect of these 5 siRNAs 
on HCV replication was shown to be prolonged over 14 days post-transfection, when 
examined (data not shown). 
We next monitored dose-response effects of each of the 5 selected siRNAs using decreasing 
siRNA doses in the range of 2000 to 4 ng (67 - 0.13 nM per µg replicon) in coelectroporation 
experiments with 5 µg of Ntat2ANeo replicon (Fig. 2b). From these experiments, inhibition 
doses 50 (ID50) were calculated for each siRNA (Fig. 2b). siRNAs si240-1a and si244 proved 
to be the most efficient inhibitors of HCV RNA replication with ID50s of 19 ng (0.64 nM) and 
33 ng (1.11 nM), respectively, while all siRNAs exhibited ID50s within the 19-141 ng range. 
The ID50 of si240-1b (127 ng) was shown to be substantially higher than that of si240-1a (19 
ng), in agreement with the fact that si240-1b is not fully homologous to Ntat2ANeo 5'NTR 
(genotype 1a), thereby demonstrating the sequence-specificity of these siRNAs. We also 
found that the co-administration of two siRNAs targeting nonoverlapping HCV sequences, 
used at suboptimal doses, resulted in additive inhibitory effects (data not shown). This might 
prove useful in future studies in which a strategy based on combined siRNAs is sought to 
prevent the occurrence of escape mutations. The five siRNAs (si205, si240-1a, si240-1b, 
si244, si313) that specifically target domain III of the HCV IRES and strongly inhibit 
subgenomic RNA replicon replication when used in the nM range were retained in the 
remaining of the study.
9Viral RNA detection in siRNA-treated cells
We next investigated whether HCV replicon RNA was eliminated in siRNA-treated cells in 
which SEAP activities were at basal level, to determine whether siRNAs were capable of 
curing replicon-containing cells. Total RNA was extracted from cells cotransfected with 
replicon and siRNA at 10 days post-transfection and analyzed for HCV RNA by semi-
quantitative RT-PCR using an HCV primer pair allowing amplification of a 1630-bp 
fragment that spans the NS3 coding region, as well as a primer pair allowing the detection of 
a housekeeping mRNA (GAPDH) for RNA quantity normalization purposes (Fig. 2c). HCV 
RNA was readily detected in cells transfected with Ntat2ANeo or cotransfected with 
Ntat2ANeo and siIRR at similar abundances (Fig. 2c, lanes 4, 5). Very low levels of residual 
transfected ∆GDD RNA molecules could be occasionally detected in these experimental 
conditions (Fig. 2c, lane 3). Viral RNA was not detected or weakly detected, at a level 
comparable to that of ∆GDD RNA, in cells cotransfected with Ntat2ANeo and si240-1a, 
si244 or si313 in duplicate experiments (Fig. 2c, lanes 8-13). HCV RNA was consistently 
detected in cells cotransfected with Ntat2ANeo and si205 (Fig. 2c, lanes 6, 7), but at lower 
levels than in cells cotransfected with Ntat2ANeo and siIRR. These results correlated well 
with inhibition levels of reporter SEAP activities and confirmed that HCV RNA replication 
was strongly inhibited, if not abolished, in cells treated with 2 µg of the three most efficient 
siRNAs (si240-1a, si244, si313). 
Effect of siRNAs in a replicon-containing cell line
In order to work with a cell culture system mimicking an established persistent infection, we 
analyzed the inhibitory capacity of siRNAs in En5-3 cells that stably contain and 
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continuously replicate Ntat2ANeo replicon. The ongoing replication of Ntat2ANeo replicon 
in these cells was reflected by >10-fold higher SEAP levels than in transient experiments 
after HCV replicon electroporation. Two µg of each siRNA were electroporated into these 
cells and their effect on HCV RNA replication was determined at different time-points. Data 
obtained at 7 days post-transfection, corresponding to cumulative SEAP levels secreted 
between days 4 and 7 post-transfection, are represented in figure 3. SEAP activity generated 
by HCV replicon in the presence of either homologous siRNA was reduced by 50% or more 
relative to that of Ntat2ANeo in mock-transfected cells. When a higher dose (5 µg) of 
siRNAs was used, SEAP activity was reduced by 70-93% (data not shown). siRNA-mediated 
inhibitory effect was not as dramatic as in cotransfection experiments, likely due in part to 
limited transfection efficiency (~70%, data not shown), permitting ongoing RNA replication 
in cells that did not receive siRNA in the transfected culture. In addition, viral RNAs 
undergoing replication within replication complexes may be less accessible to transfected 
siRNAs than cotransfected viral RNAs. Nonetheless, we demonstrated strong, dose-
dependent inhibitory potency of HCV domain III-specific siRNAs in cells supporting 
continous HCV RNA replication.
Effect of siRNAs on G418-resistant cell clone formation
We next addressed the question of the efficacy of siRNAs on HCV genome replication in 
cells placed under selective pressure and determined whether HCV escape to specific siRNA 
treatment occurred. In these experiments, we used the HCV replicon-free subclone 2-3c of 
Huh7 cells [32] and either Ntat2ANeo or NNeo replicon. In contrast to Ntat2ANeo, NNeo 
replicon (see Fig. 1b; [20]) contains a 5'NTR derived from the N strain of genotype 1b and 
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only encodes neomycine phosphotransferase gene in the first cistron. 2-3c cells were 
coelectroporated with either Ntat2ANeo or NNeo replicon and each siRNA, placed under 
G418 selective pressure, and G418-resistant cell clones were numbered at 21 days post-
transfection. Figure 4 shows means of 2-3 experiments carried out with each replicon, which 
were pooled for siRNAs homologous to both replicons (si205, si244, si313). A mean of 
34,000 resistant cell clones ± 23800 was obtained after transfection of HCV replicon alone. 
Data are represented with respect to 10,000 G418-resistant clones in each experiment. 
Treatment with all HCV-specific siRNAs resulted in substantial reduction of the number of 
G418-resistant cell clones (Fig. 4). siRNA si205 reduced by ~2 logs the formation of G418-
resistant cell clones, whereas si244 and si313 reduced cell clone formation by 3 logs or more 
(Fig. 4a), which is in good correlation with results obtained in the SEAP reporter system. 
Both si240-1a and si240-1b were more efficient on their homologous target than on 
heterologous targets (Fig. 4b). The nature and the position of the mismatch between si240 and 
its target (G:U and A:C for si240-1a on HCV genotype 1b and si240-1b on genotype 1a, 
respectively, at nucleotide 18 of the siRNA antisense strand) are reasonably well tolerated by 
the RNAi machinery, resulting in ~ 2 log reduction in G418-resistant cell clone formation, an 
inhibition that was, however, 1-1.5 log less efficient than on homologous targets. These 
experiments confirmed, as already described [28, 29, 31], that perfect base pairing between 
siRNAs and targeted mRNA is required for most effective silencing. 
To look for potential emergence of siRNA escape mutants, several G418-resistant cell clones 
obtained after a single treatment with each siRNA were isolated and independently amplified. 
The 5'NTRs of the HCV replicon RNAs recovered from 3-13 cell clones for each siRNA 
were reverse-transcribed and PCR amplified. Resulting PCR products were subjected to 
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sequencing. No nucleotide substitution was found within or in the vicinity of the siRNA-
targeted region of the HCV replicon RNAs. These data suggest that either a single siRNA 
treatment may not be sufficient to select for HCV replicon escape mutants in this system, or 
that replication competence does not tolerate nucleotide variation in this genomic region. 
Inhibitory effect of siRNAs on virus replication in cell culture
We sought to determine whether siRNAs si240-1a, si244, and si313, that were shown to be 
most efficient in inhibiting the replication of HCV subgenomic replicons both transiently and 
under selective pressure, were also capable of efficiently blocking virus infection in cell 
culture. We utilized the JFH-1 strain of HCV genotype 2a that was shown to infect Huh7 and 
Huh7-derived cell lines and produce infectious particles [4]. This in vitro infectious system 
hence recapitulates the entire HCV life cycle. Sequences of si240-1a and si313 were perfectly 
homologous to the 5'NTR sequence of this genotype 2a strain. In contrast, si244 hybridized to 
the JFH-1 5'NTR with a C:A mismatch at the third position of the siRNA antisense strand 
(see Fig. 1c). Such a mismatch at the 5' end of the antisense strand is expected to hamper 
RNA interference [29, 33]. For this reason, we also used an engineered chimeric virus that 
contains 5'NTR and core-coding sequences derived from genotype 1a within the backbone of 
the JFH-1 genome (JFH-1/C(+)6-1a; Delgrange et al., unpublished data). The three siRNA 
sequences are homologous to the 5'NTR of this chimeric virus. To monitor the inhibitory 
effect of siRNAs on HCV infection, HuAP cells were electroporated with each siRNA and 
infected with either JFH-1 or the chimeric 1a/2a virus JFH-1/C(+)6-1a. Infected cells were 
probed by immunofluorescence with anti-core (Fig. 5a) or anti-E2 (data not shown) 
monoclonal antibodies. Most cells in the control cultures infected with JFH-1/C(+)6-1a (Fig. 
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5a, left panel) or JFH-1 (Fig. 5a, right panel) were antigen-positive. Non-specific siIRR had 
no detectable effect on HCV infection (Fig. 5a). In contrast, HCV-specific siRNA si313 
reduced considerably the number of cells infected with either JFH-1 or the chimeric virus 
(Fig. 5a). Similarly, si244 inhibited efficiently infection with the 1a/2a chimeric virus (Fig. 
5a, left), but had only a weak effect, if at all, on JFH-1 infection (Fig. 5a, right), consistent 
with the existing mismatch between si244 and genotype 2a 5'NTR (see Fig. 1c). Interestingly, 
si240-1a siRNA also appeared to have a higher inhibitory effect on the infection with the 
chimeric virus (Fig. 5a, left) than with JFH-1 (Fig. 5a, right), in spite of perfect homology 
with the 5'NTR sequence of both viruses. We hypothesized that these differential effects of 
si240-1a might be linked to delayed replication kinetic of the chimeric 1a/2a virus, as 
compared to JFH-1 (Delgrange et al., unpublished data), a phenotype that may impact on 
target/siRNA ratios at early times post-infection. The effect of the three siRNAs on both 
viruses was also monitored by western blot analysis of E2 expression in infected cells (Fig. 
5b). Data confirmed that si313 was the most efficient siRNA, which resulted in complete 
inhibition of E2 expression in cells infected with either JFH-1 or JFH-1/C(+)6-1a. 
To verify that virus production from siRNA-treated cells was accordingly reduced, viral 
particles were titrated in supernatants from cells transfected with each siRNA and infected 
with either JFH-1 or the chimeric virus, both by real-time quantitative RT-PCR (genome 
equivalents, g.e., Fig. 5c) and by determination of infectious focus forming units (FFU)
(Table 2). For all siRNAs, quantification of virus production in siRNA-treated cultures (Fig. 
5c, Table 2) was in good agreement with core and E2 intracellular expression levels (Fig. 5a-
b). In particular, supernatants from si313-treated, HCV-infected cells exhibited a >92% 
reduction in ge/mL titer and a >96% reduction in FFU/mL infectious titer, compared to mock-
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treated, HCV-infected cells. Altogether, these data demonstrate that HCV 5'NTR-specific 
siRNAs are capable of strongly inhibiting virus production in cell culture.
DISCUSSION
To explore RNAi as a potential new therapeutical approach against HCV infection, one of the 
reasons why we chose to target domain III of the HCV 5’NTR resides in that domain III 
contains well conserved nucleotide sequences across all HCV genotypes (Table 1) [34]. The 
high conservation degree of these sequences may be required to preserve virus functions, 
since this 5'NTR domain controls the initiation of polyprotein translation and modulate RNA 
replication [23, 24]. Recent NMR and electron cryomicroscopy studies of domain III [22, 35, 
36] helped identify the structure/function relationship of the various III subdomains. These 
studies suggested that subdomains IIIa/c and IIId, as well as subdomain IIIf that forms a 
pseudoknot structure (Fig. 1a) directly contact the 40S subunit body and act synergistically 
for the proper positioning of the AUG codon. In the present work, si240 and si244, that 
hybridize to subdomain IIId, and si313, that essentially hybridizes to the IIIf pseudoknot, thus 
target regions that are essential for IRES structural integrity and function. These three 
siRNAs proved able, at low doses in the nM range, to substantially reduce or even abolish 
HCV subgenomic RNA replication, as measured by reporter SEAP activities and G418-
resistant cell clone formation (Figs. 2, 4), and resulted in the elimination of HCV replicons 
from treated cells (Fig. 2c). Importantly, we also demonstrated that these siRNAs, particularly 
si313, considerably limited HCV infection in cell culture, using two HCV strains that can be 
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propagated in Huh7-derived cells, the JFH-1 strain of HCV genotype 2a [4] and a chimeric 
derivative of JFH-1 carrying 5'NTR and core sequences of HCV genotype 1a (Delgrange et 
al., unpublished data). Our data contrast with those obtained by others who concluded to 
relative siRNA-resistance of domains II [17] and III [17, 19] of HCV 5'NTR, incriminating 
the reduced accessibility of these domains given their association with different proteins and 
factors involved in translation. Our data thus indicate that regions involved in complex 
secondary and tertiary structures should not be disregarded as targets for RNAi and underline 
the importance of siRNA design [25, 26]. In contrast, two of the siRNAs tested in the present 
study (si214 and si284, targeting domain IIIc and IIIe, respectively) exhibited poor or only 
transient inhibitory effect on HCV RNA replication (Fig. 2a). Interestingly, siRNAs with 
sequence identical to that of si284 were reported to have discrepant effects in cells supporting 
autonomous replication of HCV subgenomic replicon in two other studies [13, 19]. These 
conflicting results may be explained by different strategies used for siRNA synthesis and/or 
delivery. In addition, the sensitivity of the replicon systems used may impact on the siRNA 
efficiencies reported. 
We observed some differences in siRNA efficiencies between transient replication systems in 
which viral target RNA and siRNA were co-introduced into cells (Figs. 2, 4), and stable 
replication systems in which siRNA was introduced in cells supporting ongoing replication of 
the viral target, whether dealing with a subgenomic replicon (Fig. 3) or genome-length 
infectious RNA (Fig. 5, Table 2). Two µg siRNA did not inhibit viral RNA replication in the 
stable subgenomic replicon system as efficiently as in cotransfection experiments (compare 
Fig. 3 and Figs. 2, 4). In addition, si240-1a and si244 led to viral RNA elimination upon 
cotransfection with subgenomic replicon (Fig. 2a), while they substantially reduced, but did 
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not abolish virus particle production (Fig. 5, Table 2). This is in spite of the fact that the 
molar ratio of siRNA over targeted HCV RNA was higher in cells stably containing HCV 
replicons or infected with virus than in cells cotransfected with replicon and siRNA. In 
another study, high doses (4000 pmol) of siRNAs proved necessary to strongly inhibit HCV 
RNA replication in subgenomic replicon-containing cells [18]. We speculate that viral RNA 
templates engaged in the replicase complex and nascent RNAs are probably not as accessible 
to the RNAi machinery as transfected viral RNAs. Our data can also be explained in part by 
the existence of a proportion of cells in the culture that were infected or supported ongoing 
viral RNA replication but did not receive siRNA, given an electroporation efficiency of ~70% 
in En5-3 and 2-3c cells (data not shown). 
The specificity of HCV siRNAs was demontrated by studying their dose-effect responses 
(Fig. 2b), as well as by using si240 to target the replicon 5’NTR from two HCV genotypes 
(1a and 1b; Figs. 2-4) and si244 to target the 5'NTR of genotype 1a or 2a virus strains (Fig. 5, 
Table 2). When used with heterologous targets, siRNAs si240-1a and si240-1b exhibited a 
noncanonical wobble base-pairing or a mismatch at the 3' end (position 18) of the siRNA 
antisense strand, respectively (Fig. 1c). For both 1a and 1b replicons, perfect base-pairing was 
preferred for maximum RNAi efficacy, but a G:U wobble and an A:C mismatch were both 
tolerated (Fig. 4). This is consistent with the fact that wobble base-pairing is known to be well 
tolerated in dsRNA helices, providing similar stability as a Watson-Crick base-pairing. In 
agreement with our data, wobble base-pairs, especially when located at the 3’ end of the 
siRNA antisense strand, were recently suggested to have no disruptive effect on RNAi [28, 
29, 33]. More surprising, but also consistent with our data, it was reported that an A:C 
mismatch was not deletorious in dsRNA structures [29]. Contrasting with these tolerated 
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mismatches between siRNA and viral target RNA, we found that a C:A mismatch at the 5' 
end of the siRNA antisense strand strongly reduced the inhibitory effect of si244 on JFH-1 
infection in cell culture (Fig. 5, Table 2), which is consistent with RNAi mechanism [29, 37]. 
Altogether, these data provide strong evidence against the involvement of a spurious 
interferon-mediated mechanism of inhibition in the suppression of viral replication observed.
The sequence of RNA viruses, such as HCV, is known to continuously evolve, resulting in 
the production of many quasi-species, due to high error rate of RNA-dependent RNA 
polymerases with no proof-reading activity. This property allows RNA viruses to escape 
rapidly to a selective pressure such as antiviral treatments, when sequence changes are 
compatible with virus functions. This holds true for anti-protease and anti-polymerase 
compounds which are currently under development for HCV [38, 39]. However, we did not 
observe, after a single siRNA treatment, the emergence of escape mutations within siRNA-
targeted genomic regions in RNA extracted from several G418-resistant cell clones. In other 
studies, siRNA-resistant viral mutants harboring single nucleotide substitutions or deletions 
within or at the vicinity of the siRNA-targeted sequence were reported to have emerged in 
cells expressing constitutively a shRNA, in the case of HIV infections [40, 41], or after 
repeated treatments with an siRNA targeting the polymerase coding sequence in the case of 
HCV subgenomic replicons [16]. The lack of escape mutations in our study could thus be 
linked to the use of a single siRNA treatment, or to the fact that siRNAs target highly 
conserved, functionally important genomic sequences, in which substitutions would not be 
compatible with translation/replication competence. Additional studies will be needed to 
discriminate between these hypotheses.
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In the perspective of evaluating the potency of siRNA-based antiviral strategies to eradicate 
persistent infections, it was recently shown that siRNAs may be used to cure in vitro
persistent infections by RNA viruses, such as poliovirus or lymphocytic choriomeningitis 
virus [30, 42]. To assay such a therapeutical strategy in animal models, synthetic siRNAs 
need to be further chemically-stabilized and formulated to be efficiently delivered. Successful 
utilization of stabilized, lipid-encapsulated siRNAs was reported in a mouse model of 
hepatitis B virus (HBV) replication [43]. In addition, organ or cell-type specific delivery of 
siRNAs has been achieved through siRNA binding to cholesterol [44] or to antibodies 
directed against cell surface antigens [45]. Synthetic shRNAs also showed more prolonged 
inhibitory effect than siRNAs in the liver of mice, as exemplified upon co-delivery of shRNA 
or siRNA targeting domain IV of the HCV IRES and plasmid DNA encoding a reporter 
protein placed under the translational control of the HCV IRES [46]. Alternatively, 
optimization of siRNA delivery may rely on the use of viral vectors allowing continuous 
synthesis of shRNAs in cells, leading to sustained RNAi [31, 47]. The control of intracellular 
shRNA production levels is, however, critical, since it has recently been reported that 
constant, high expression of shRNAs in the liver could be lethal in mouse models [48]. 
Nevertherless, controlled dose of siRNA or expression of shRNA have already proven 
efficient and safe in several animal models of viral infection, including in a mouse model of 
HBV infection [47], a rhesus macaque model of Severe Acute Respiratory Syndrome 
associated coronavirus infection [49], and mouse models of West Nile virus or Japanese 
encephalitis virus infection [31]. 
In the present study, we have identified promising anti-HCV siRNAs (si313 and to a lesser 
extent si244, si240) that target highly conserved sequences in domain III of the 5'NTR and 
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efficiently silence HCV infection in cell culture. It becomes now possible to monitor the 
effect of these siRNAs in vivo using a tamarin / marmoset primate model of infection with a 
chimeric GB virus B containing HCV domain III of the HCV IRES, that we have previously 
described [8]. 
Note added in proof: During revision of this manuscript, Kanda et al. (J. Virol. 2007, 81:669) 
reported that delivery of an HCV 5’NTR-specific shRNA to hepatoma cell lines infected by 
HCV resulted in the reduction of viral production.
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MATERIALS & METHODS
Cells and viruses.  Hepatoma cell lines, 2-3c [32], En5-3 [21], and HuAP are derived from 
the hepatocarcinoma cell line Huh7, and were cultured in Dulbecco’s modified Eagle medium 
(Invitrogen, Cergy-Pontoise, France) supplemented with 10% fetal calf serum, 100U/mL 
penicillin and 100µg/mL streptomycin. En5-3 cells stably express secreted alkaline 
phosphatase (SEAP) under the control of the HIV LTR promoter [21], and were cultured in 
the presence of 2µg/mL blasticidin (InvivoGen, Toulouse, France). En5-3 cells supporting 
autonomous replication of Ntat2ANeo HCV replicon were cultured in the presence of 
2µg/mL blasticidin and 0,5mg/mL geneticin (G418, Invitrogen, Cergy-Pontoise, France). 
Genotype 2a JFH-1 and chimeric JFH-1/C(+)6-1a virus stocks were generated by transfection 
of HuAP cells with corresponding in vitro transcribed genomic RNAs. Plasmid pJFH-1 
containing the genome-length cDNA of the JFH-1 isolate of HCV genotype 2a [Genbank 
accession number AB047639, Ref. 4] was generously provided by T. Wakita. Plasmid pJFH-
1/C(+)6-1a was derived from pJFH-1 by substituting nucleotides 154-341 of the 5' 
nontranslated region, as well as the capsid coding sequence by corresponding sequences of 
the H77 strain of genotype 1a (Delgrange et al., will be described elsewhere). Plasmids pJFH-
1 and pJFH-1/C(+)6-1a were linearized with XbaI and treated with Mung Bean nuclease prior 
to in vitro transcription using MEGAscriptTM kit (Ambion, Cambridgeshire, United 
Kingdom). HuAP cells were electroporated with in vitro transcribed RNA, as previously 
described [50], and supernatants collected 8-10 days post-transfection were used to re-infect 
naïve HuAP cells. Supernatants collected at 10 days post-infection (p.i.) were used as virus 
stocks and stored at -80°C. 
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Design and synthesis of siRNAs.  siRNAs targeting HCV IRES were designed using 
previously described criteria [25, 26]. The sequence of the sense-strand of each siRNA 
selected is shown in Table 1. siRNAs are referred to by the nucleotide position within the 
genome of the H77 strain of HCV genotype 1a [27] that corresponds to the first nucleotide 
targeted by the siRNA antisense strand. si240 was synthesized with a sequence homologous 
to HCV subtype 1a or 1b, i.e. containing a U (si240-1a) or a C (si240-1b) residue at position 
18 of the siRNA antisense strand. An irrelevant siRNA, named siIRR, targets the 5’NTR of 
the Sabin strain of poliovirus type 3 [30] and was used as negative control in this study. The 
sequence of all siRNAs was compared to known genes by a BLAST search within the 
GenBank database and no significant homology to other genes was found. The two strands of 
each siRNA were chemically synthesized at the Institut Pasteur ("Plate-forme 7") and 
annealed at a final concentration of 500 pmol/µL, as previously described [25]. The quality 
and quantity of hybridized siRNAs were analyzed by electrophoresis on nondenaturing 3% 
agarose gels. 
HCV subgenomic replicons and in vitro transcriptions.  Two dicistronic, subgenomic 
HCV replicons that encode a selectable reporter gene, neomycine phosphotransferase (Neo) 
were used in this study (see Fig. 1). These replicon cDNAs, kindly provided by S.M. Lemon, 
are inserted downstream of the T7 RNA polymerase promoter and have been previously 
described as pNNeo/3-5B [20] and pNtat2Aneo [21]. We will refer to these replicons as 
NNeo and Ntat2ANeo, respectively, in this study. NNeo and Ntat2ANeo each carry a cell 
culture adaptive mutation, R2889G and S2005I, respectively. Both replicon cDNAs are 
derived from the cDNA of the N strain of genotype 1b HCV with the exception of the 5’NTR 
sequence of the Ntat2ANeo, which is derived from the H77 strain of HCV genotype 1a. 
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Ntat2ANeo RNA encodes HIV Tat protein fused to the 2A protease of foot-and-mouth 
disease virus (FMDV) followed by Neo [21]. Upon transfection of En5-3 cells with 
Ntat2ANeo replicon, the expression of Tat-2A drives the synthesis of secreted SEAP [21]. 
cDNAs bearing a 30-nucleotide deletion including the 3 codons (GDD) of the active site of 
the RNA polymerase NS5B within the backbone of NNeo and Ntat2ANeo [20, 21], referred 
to as ∆GDD, were used as replication-deficient RNAs. Plasmid DNAs were linearized with 
XbaI prior to in vitro transcription using T7 MEGAscript reagents (Ambion, Cambridgeshire, 
United Kingdom). DNA template was removed by treatment with Turbo DNase (Ambion, 
Cambridgeshire, United Kingdom) and RNAs were purified by phenol-chloroform 
extractions and precipitated with ethanol. The quality and quantity of replicon RNAs were 
analyzed by electrophoresis on a non-denaturing 0.8% agarose gel and by optical density 
measurements.
Cell transfections. En5-3 or 2-3c cells (2x106) were electroporated with 5µg replicon RNA, 
or co-electroporated with 5µg replicon RNA and various doses of each siRNA, in a 4 mm-gap 
width cuvette by applying one pulse at 240V, 900µF (EasyjecT Plus, Geneflow Ltd, 
Staffordshire, United Kingdom). Cells were resuspended in complete medium immediately 
after the pulse and seeded at various concentrations. En5-3 cells supporting autonomous 
replication of Ntat2ANeo replicon were similarly transfected by electroporation with each 
siRNA. 
Measurement of SEAP activity. En5-3 transfected cells (4x105) were seeded in 6-well plates 
and supernatants were collected at 1, 2, 3, 4 and 7 days after electroporation and replaced 
with fresh medium. SEAP activity was measured in supernatant aliquots with the Phospha-
Light™System (Applied Biosystems/ Tropix, Courtaboeuf, France) using a luminescent 
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substrate according to the manufacturer’s recommendations. Luminescent signals were read 
for 1 s using a Lumat LB 9507 luminometer (Berthold Technologies, Thoiry, France).
G418-resistant cell clone selection.  To select for G418-resistant cell clones, variable 
fractions of 2-3c transfected cells were seeded in 100 mm-diameter dishes and supplemented 
with NNeo-∆GDD or Ntat2ANeo-∆GDD transfected cells to adjust the final number of cells 
to 5x105 cells per dish. Twenty-four to 48 hours following transfection, cells were placed 
under the selective pressure of 0.5 mg/mL geneticin (G418, Invitrogen, Cergy-Pontoise, 
France) for 3 weeks, with medium replacement twice a week. G418-resistant cell clones 
supporting viral RNA replication were fixed and stained with a 0.1% crystal violet solution, 
or selected and expanded under selective pressure for viral RNA sequencing.
Viral RNA sequencing.  Total RNA was extracted from expanded siRNA-resistant clones 
with TRIzol reagent (Invitrogen, Cergy-Pontoise, France). Viral RNA was reverse transcribed 
and amplified with HCV specific primers designed to generate PCR products spanning 
nucleotides (nts) 100 to 451, using the SuperScript One-Step RT-PCR kit with Platinum Taq 
(Invitrogen, Cergy-Pontoise, France). Sequencing reactions were carried out on uncloned RT-
PCR products using Big Dye Terminator version 1.1 kit (Applied Biosystems, Courtaboeuf, 
France) and analysed on a ABI 3700 capillary DNA sequencer (Applied Biosystems, 
Courtaboeuf, France).
Detection of viral RNA by semi-quantitative RT-PCR. En 5-3 transfected cells (2x105) 
were seeded in 6-well plates (duplicate wells per transfection) and cultured for 4 days, then 
trypsinized and passaged at a 1:5 dilution in new 6-well plates. At day 10 post-transfection, 
total RNA was extracted independently from duplicate wells using RNeasy mini kit (Qiagen, 
Courtaboeuf, France). Five micrograms of total cellular RNA were heat-denatured at 65°C for 
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5 min and used as template for reverse transcription with 50 U of Superscript II reverse 
transcriptase (Invitrogen, Cergy-Pontoise, France) and 250 ng of random hexanucleotide 
primers (Roche, Meylan, France) for 50 min at 42°C. Resulting cDNAs were treated with 2 U 
of RNaseH (Invitrogen, Cergy-Pontoise, France) for 30 min at 37°C, and purified using 
QIAquick PCR purification kit (Qiagen, Courtaboeuf, France). One fifth of the cDNA was 
used to program PCR reactions with either HCV-specific primers that allowed amplification 
of a fragment spanning nts 3457-5085 of the N strain of HCV genotype 1b, or primers 
specific for cellular housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), to normalize for total RNA content. PCR reactions were performed using 
Platinum Taq DNA polymerase (Invitrogen, Cergy-Pontoise, France) under the following 
cycling conditions : 1 cycle at 94°C for 3 min, followed by 35 cycles of : 30 s at 94°C ; 30 s 
at 55°C ; 1.5 min at 72°C. PCR products were analyzed by electrophoresis on 1% agarose 
gels.
Infection with HCV and indirect immunofluorescence analysis. HuAP cells (4x106) were 
electroporated with 2µg of siRNA, and 5x104 electroporated cells were seeded on coverslips 
in 24-well plates and subsequently infected at 16 h post-transfection with JFH-1 or JFH-
1/C(+)6-1a virus stocks at ~ 1 FFU per cell. After a 2 h incubation at 37°C, virus inoculum 
was washed off and cells were fed with culture medium. At 42 h p.i., cells were fixed and 
processed for core detection by indirect immunofluorescence, as previously described [50], 
using anti-core monoclonal antibody (Mab) ACAP27 (kindly provided by J.F. Delagneau, 
Bio-Rad, France). Cells were counterstained with Hoechst dye to detect nuclei. For titration 
of infectious viral particles, 5x104 HuAP cells were infected with 1:10 dilutions of 
supernatants from cells transfected with siRNAs and infected with HCV. Foci of infected 
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cells were detected by immunofluorescence with anti-core Mab at 72 h p.i. and counted to 
determine titers in FFU/mL. 
Immunoblot analysis of HCV-infected cells. HuAP cells (4x106) seeded in 24-well plates 
were lyzed in 50 mM Tris HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 0.5% (v/v) Igepal 
buffer containing a mixture of protease inhibitors (Complete, Roche, Meylan, France) and 
processed for E2 or -actin detection by immunoblot analysis as previously described [50], 
using anti-E2 MAb 3/11 [51] or anti--actin Mab (Sigma-Aldrich, Saint Quentin Fallavier, 
France), respectively. 
Quantification of virus production by quantitative RT-PCR. Viral RNAs were isolated 
from cell culture supernatants using QIAamp Viral RNA kit (Qiagen, Courtaboeuf, France) 
and quantified by real-time TaqMan RT-PCR using primer pair and probe targeting a 
sequence spanning nts 130 to 290 within the HCV 5’NTR : FP 5'-
CGGGAGAGCCATAGTGG -3' ; RP 5'- AGTACCACAAGGCCTTTCG -3' ; Probe 5'-
FAM- CTGCGGAACCGGTGAGTACAC -TAMRA -3'. Assays were performed using 
Taqman One-Step RT-PCR Master Mix Reagents and an ABI PRISM 7700 Sequence 
Detector instrument (Applied Biosystems, Courtaboeuf, France), according to the 
manufacturer’s instructions.
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Table 1 : Sequences of siRNAs used to target domain III of the internal ribosome entry site of 
HCV genome. 
1 siRNA numbering corresponds to the first nucleotide of the H77 strain of HCV genotype 1a 
[27] targeted by the 21-nucleotide siRNA antisense-strand.
2 Degree of conservation (%) of each siRNA-targeted sequence among 159 HCV sequences 
of all genotypes, as found in the Los Alamos National Laboratory database 
(http://hcv.lanl.gov/content/hcv-db/index). NA: not applicable
siRNA 1 siRNA sense-strand (5' 3')
Conservation 
degree (%) 2
si205  CCCGCUCAAUGCCUGGAGATT 73.6
si214 UGCCUGGAGAUUUGGGCGUTT 73.6
si240-1a CAAGACUGCUAGCCGAGUATT 28.9
si240-1b CGAGACUGCUAGCCGAGUATT 62.3
si244 ACUGCUAGCCGAGUAGUGUTT 71.1
si284 GUACUGCCUGAUAGGGUGCTT 98.7
si313 CCCGGGAGGUCUCGUAGACTT 98.1
siIRR CGUUUUACUCCUUAACUUATT  NA
34
siRNA Virus production 1
JFH-1 JFH-1/C(+)6-1a
Ø 8.4 x 103 (100) 7.1 x 103 (100)
siIRR 7.8 x 103  (93) 6.6 x 103  (93)
si240-1a 2.9 x 103  (35) 1.0 x 103  (14)
si244 5.1 x 103  (61) 1.1 x 103  (15)
si313 1.5 x 102   (2) 3.0 x 102   (4)
Table 2 : Effect of siRNAs on HCV production. 
1 Viral titers in the supernatants of HuAP cells transfected with each siRNA and infected with 
the indicated virus are expressed in FFU/mL, as well as, in parentheses (%) relative to virus 
production from mock-transfected cultures (Ø) set at 100%. 
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FIGURE LEGENDS
Figure 1 : HCV-specific siRNAs and HCV replicons used.
(a) The footprints of the 7 HCV-specific siRNAs selected to target the IRES are represented 
on the schematic structure of domains III-IV of the 5'NTR from the H77 strain of HCV 
genotype 1a [2]. siRNA si240 targets a viral sequence that contains a nucleotide change in 
HCV genotype 1a and 1b sequences, as indicated. (b) The two replicons used in this study, 
Ntat2Aneo [21] and NNeo [20] with 5'NTRs derived from HCV genotype 1a and 1b strains, 
respectively, are schematically represented, with cell culture adaptive mutations (S2005I in 
NS5A and R2889G in NS5B, respectively) indicated by arrowheads. Both replicons encode 
neomycine phosphotransferase (Neo) C-terminally fused to either HIV Tat protein followed 
by foot and mouth disease virus (FMDV) autocatalytically cleaved 2A protein (Ntat2ANeo) 
or to a few amino acid residues from core protein (∆C in NNeo). (c) The base pairing of 
si240-1a and si240-1b with 5'NTR sequences of replicons Ntat2ANeo (1a genotype) and 
NNeo (1b genotype), and of si244 with 5'NTR sequence of virus JFH-1 (2a genotype) is 
shown. Viral RNA/siRNA duplexes are delineated by dotted lines. Nucleotide mismatches 
between siRNAs and HCV sequences are boxed and their position within the siRNA anti-
sense strand is indicated. 
Figure 2 : siRNAs inhibit efficiently transient replication of reporter HCV replicon.
(a) Graphs represent secreted phosphatase alkaline (SEAP) activities (arbitrary units) in 
supernatants of En5-3 cell cultures electroporated with no RNA (Mock), 5 µg RNA from 
HCV Ntat2ANeo replicon (Ntat2ANeo) or a non-replicative HCV RNA (∆GDD), or 
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coelectroporated with 5µg of HCV Ntat2ANeo replicon and 2µg of each indicated siRNA. 
Each time point corresponds to the amount of SEAP accumulated over 24-hour periods 
during the first 4 days after transfection, and the last point at 7 days post-transfection 
corresponds to SEAP activity accumulated between days 4 and 7 post-transfection. Each 
point represents mean ± standard deviation of at least 3 experiments. Data are represented on 
a logarithmic scale. (b) Effects of increasing doses of each siRNA (white to dark grey bars for 
4 to 2000 ng doses) are represented as percentages of SEAP activity inhibition, calculated 
relatively to SEAP activity obtained with replicon Ntat2ANeo RNA alone. Each histogram 
bar represents mean ± standard deviation of multiple independent experiments. (c) Identical 
amounts of total RNA extracted from cells transfected with no RNA (Mock), HCV 
Ntat2ANeo replicon (Ntat2ANeo), or non-replicative HCV RNA (∆GDD), or 
coelectroporated with 5µg of HCV Ntat2ANeo replicon and 2µg of each indicated siRNA 
were reverse transcribed and amplified by PCR using HCV 5'NTR-specific primers (upper 
gel) or housekeeping gene GAPDH-specific primers (lower gel). A control reaction 
performed in the absence of template RNA (No RNA) was analyzed in parallel on 1% 
agarose gels. PCR products obtained with RNA extracted from two independent cell cultures 
treated with HCV-specific siRNAs are shown. DNA molecular weight markers are shown on 
the left of the gels. Filled and open arrowheads point to HCV and GAPDH-specific RT-PCR 
products, respectively. 
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Figure 3 : Inhibitory effect of siRNA treatment in cells supporting autonomous replication of 
HCV replicon. 
SEAP activities in supernatants of En5-3 cells supporting autonomous replication of 
Ntat2ANeo replicon transfected with 2µg of each indicated siRNA were determined at 7 days 
post-transfection and represented relative to SEAP activity present in mock-transfected cells, 
set at 100%. Each bar represents mean ± standard deviation of 4 experiments. 
Figure 4 : siRNAs protect from establishment of HCV replicon-containing cell clones.
(a) Numbers of G418-resistant 2-3c cell clones obtained 3 weeks after cotransfection of 5µg 
of Ntat2ANeo or NNeo replicon and 2µg of each indicated siRNA that is homologous to both 
HCV replicons (si205, si244, si313) or irrelevant siRNA (siIRR) are expressed relative to 
10,000 resistant cell clones obtained after transfection of HCV replicon alone (Ø). Values 
(means ± standard deviations of independent transfections) are plotted on a logarithmic scale. 
The effects of si240-1a or si240-1b treatment on replicon Ntat2ANeo (b) and NNeo (c) are 
represented separately. Mismatches present at position 18 of the siRNA antisense strand are 
indicated on top of the bars corresponding to heterologous targets.
Figure 5 : HCV 5'NTR-specific siRNAs silence virus replication in cell culture. 
(a) HuAP cells were transfected with no siRNA (Ø), irrelevant siRNA (siIRR) or the 
indicated HCV-specific siRNA (si240-1a, si244, si313), then infected at 16 h post-
transfection with either JFH-1 strain of HCV genotype 2a (right panels) or a chimeric JFH-1 
virus containing 5'NTR-C sequences from the H77 strain of HCV genotype 1a (JFH-1/C(+)6-
1a, left panels). At 42 h p.i., cells were fixed and processed for core detection by 
38
immunofluorescence and counterstained with Hoechst dye to visualize nuclei. Overlayed 
images (x10) are shown. Control cells that were mock-transfected and mock-infected (Mock) 
were processed in parallel. (b) Extracts from siRNA-transfected and HCV-infected cells 
collected at 42 h p.i. were analyzed by western blotting for expression of E2 glycoprotein 
(upper gel) and cellular -actin (lower gel) as loading controls. (c) Virus yields in 
supernatants from siRNA-transfected and HCV-infected cells collected at 42 h p.i. were 
quantified in genome equivalents /mL by real-time TaqMan RT-PCR and expressed relative 
to virus production in the absence of siRNA treatment, set at 100% (mean ± standard 
deviation of duplicates in 2 independent experiments). 
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